Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EBITDA (2016 - 2025)

Historic EBITDA for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$19.0 million.

  • Altimmune's EBITDA rose 1558.81% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.1 million, marking a year-over-year increase of 1855.37%. This contributed to the annual value of -$95.0 million for FY2024, which is 771.22% down from last year.
  • Altimmune's EBITDA amounted to -$19.0 million in Q3 2025, which was up 1558.81% from -$22.2 million recorded in Q2 2025.
  • Altimmune's 5-year EBITDA high stood at -$14.9 million for Q1 2021, and its period low was -$33.5 million during Q3 2021.
  • For the 5-year period, Altimmune's EBITDA averaged around -$22.4 million, with its median value being -$22.2 million (2025).
  • As far as peak fluctuations go, Altimmune's EBITDA plummeted by 27924.15% in 2021, and later skyrocketed by 2940.14% in 2022.
  • Over the past 5 years, Altimmune's EBITDA (Quarter) stood at -$23.9 million in 2021, then grew by 9.65% to -$21.6 million in 2022, then tumbled by 46.04% to -$31.5 million in 2023, then rose by 26.06% to -$23.3 million in 2024, then increased by 18.52% to -$19.0 million in 2025.
  • Its EBITDA was -$19.0 million in Q3 2025, compared to -$22.2 million in Q2 2025 and -$19.6 million in Q1 2025.